Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing

Serving leading biopharmaceutical companies globally:

McKinsey
Medtronic
Merck
US Department of Justice
Chubb
Fuji
Mallinckrodt
Fish and Richardson
Deloitte
Colorcon

Generated: December 10, 2017

DrugPatentWatch Database Preview

CARDENE IN 4.8% DEXTROSE IN PLASTIC CONTAINER Drug Profile

« Back to Dashboard

Which patents cover Cardene In 4.8% Dextrose In Plastic Container, and what generic alternatives are available?

Cardene In 4.8% Dextrose In Plastic Container is a drug marketed by Chiesi Usa Inc and is included in one NDA. There are four patents protecting this drug.

This drug has twenty-three patent family members in eleven countries.

The generic ingredient in CARDENE IN 4.8% DEXTROSE IN PLASTIC CONTAINER is nicardipine hydrochloride. There are eleven drug master file entries for this compound. Fifteen suppliers are listed for this compound. Additional details are available on the nicardipine hydrochloride profile page.

Summary for CARDENE IN 4.8% DEXTROSE IN PLASTIC CONTAINER

Drug patent expirations by year for CARDENE IN 4.8% DEXTROSE IN PLASTIC CONTAINER

Medical Subject Heading (MeSH) Categories for CARDENE IN 4.8% DEXTROSE IN PLASTIC CONTAINER

US Patents and Regulatory Information

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Patent Submitted Product Substance Delist Req. Exclusivity Expiration
Chiesi Usa IncCARDENE IN 4.8% DEXTROSE IN PLASTIC CONTAINERnicardipine hydrochlorideINJECTABLE;INTRAVENOUS019734-002Jul 31, 2008RXYesYes► Subscribe► Subscribe► SubscribeY► Subscribe
Chiesi Usa IncCARDENE IN 4.8% DEXTROSE IN PLASTIC CONTAINERnicardipine hydrochlorideINJECTABLE;INTRAVENOUS019734-002Jul 31, 2008RXYesYes► Subscribe► Subscribe► Subscribe► Subscribe
Chiesi Usa IncCARDENE IN 4.8% DEXTROSE IN PLASTIC CONTAINERnicardipine hydrochlorideINJECTABLE;INTRAVENOUS019734-002Jul 31, 2008RXYesYes► Subscribe► Subscribe► SubscribeY► Subscribe
Chiesi Usa IncCARDENE IN 4.8% DEXTROSE IN PLASTIC CONTAINERnicardipine hydrochlorideINJECTABLE;INTRAVENOUS019734-002Jul 31, 2008RXYesYes► Subscribe► Subscribe► Subscribe► Subscribe
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Non-Orange Book Patents for Tradename: CARDENE IN 4.8% DEXTROSE IN PLASTIC CONTAINER

For Orange Book-listed patents (shown in the main table above) generic applications must certify that the listed patents are expired, invalid, or will not be infringed by generic entry.

The non-Orange Book patents listed below do not require formal certifications, so they do not automatically impede generic entry. Instead, they represent potential opportunities for branded firms to block generic entry through patent infringment challenges.

Patent No. Title Estimated Patent Expiration
7,659,290Methods of preparing pre-mixed, ready-to-use pharmaceutical compositions► Subscribe
9,549,994Compositions of nicardipine and sulfoalkylated .beta.-cyclodextrin► Subscribe
9,370,586Methods of preparing pre-mixed, ready-to-use pharmaceutical compositions► Subscribe
This preview shows a limited data set
Subscribe for full access, or try a Trial

The estimated expiration dates shown above are derived by simply adding 20 years to the priority date.
Because of the complexity of determining patent expiration dates it is advisable to have patent counsel verify freedom to operate.

Export unavailable in trial.
Subscribe for complete access.

International Patent Family for Tradename: CARDENE IN 4.8% DEXTROSE IN PLASTIC CONTAINER

Country Document Number Estimated Expiration
Israel194800► Subscribe
Mexico2008013407► Subscribe
Canada2895102► Subscribe
South Korea20090040258► Subscribe
South Korea20090037388► Subscribe
BrazilPI0710287► Subscribe
BrazilPI0709617► Subscribe
Canada2649779► Subscribe
New Zealand572226► Subscribe
New Zealand572225► Subscribe
This preview shows a limited data set
Subscribe for full access, or try a Trial

The estimated expiration dates shown above are derived by simply adding 20 years to the priority date.
Due to the complexity of determining patent expirations even in a single country, compounded by the diversity of global patent laws, it is advisable to have patent counsel verify freedom to operate.

Export unavailable in trial.
Subscribe for complete access.

« Back to Dashboard

For more information try a trial or see the database preview and plans and pricing

Serving leading biopharmaceutical companies globally:

Teva
Queensland Health
Federal Trade Commission
Julphar
Farmers Insurance
Argus Health
QuintilesIMS
Citi
Mallinckrodt
US Army

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.

Copyright 2002-2017 thinkBiotech LLC
ISSN: 2162-2639

Secure SSL Encrypted
Privacy and Cookies
Terms & Conditions

Follow DrugPatentWatch:

botpot